Co-Diagnostics Inc
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Co-Diagnostics Inc’s stock with a target price of $2, indicating potential growth.
Financial Health
Co-Diagnostics is performing well with strong revenue and cash flow, indicating solid business health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CODX
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small‑cap volatility
CODX’s microcap status can lead to big price swings on news or results; this creates opportunity but also higher risk and lower liquidity.
Diagnostic tech focus
Proprietary CoPrimer PCR assays are central to its offering; tech adoption and validation are key commercial levers, though outcomes are uncertain.
Partnerships and approvals
New regulatory clearances or distribution deals can drive growth, but regulatory hurdles and competitive bids may delay impact.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Thermo Fisher Scientific, Inc.
Thermo Fisher provides a range of services and products that help customers advance their research, solve complex analytical challenges, improve patient diagnostics, and increase laboratory productivity.
Intuitive Surgical, Inc.
A healthcare company that develops, manufactures, and markets robotic-assisted surgical systems for procedures in multiple specialties
